Juan-Carlos Laguna

Dr. Juan-Carlos Laguna

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2024 in American Society of Clinical Oncology Educational Book
Verified
Journal Article
Closed access
JLJuan-Carlos Laguna
Juan-Carlos Laguna
MTMarco Tagliamento
Marco Tagliamento
Matteo LambertiniMatteo Lambertini
Matteo Lambertini
JHJames Hiznay
James Hiznay
LMLaura Mezquita
Laura Mezquita
Lung cancer has traditionally been associated with advanced age; however, its increasing incidence among young adults raises concerning questions regarding its etiology and unique considerations for this population. In contrast to the older population, the onset of lung cancer at younger age may be attributed to a complex interplay of incompletely understood individual susceptibility and prevalent environmental risk factors beyond tobacco smoke exposure, such as radon gas and air pollution, which are widespread globally. Consequently, this leads to distinct clinical and molecular profiles, requiring a tailored approach. Furthermore, a diagnosis of cancer represents a threatening event during the prime years of a young person's life, prompting concern about career development, social aspects, fertility aspirations, and physical independence. This poses significant additional challenges for health care professionals in a field that remains underexplored. This comprehensive review recognizes lung cancer in young adults as a distinct entity, exploring its clinical and molecular characteristics, diverse predisposing factors, and priorities in terms of quality of life, with the aim of providing practical support to oncologists and enhancing our understanding of this under-researched population.

6 August 2022 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
JLJuan-Carlos Laguna
Juan-Carlos Laguna
TCTim Cooksley
Tim Cooksley
SAShin Ahn
Shin Ahn
NTNikolaos Tsoukalas
Nikolaos Tsoukalas
TOThein Hlaing Oo
Thein Hlaing Oo
TGthe MASCC Hemostasis Study Group
the MASCC Hemostasis Study Group

29 March 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
MHMarta García de Herreros
Marta García de Herreros
JLJuan-Carlos Laguna
Juan-Carlos Laguna
JPJoan Padrosa Pulido
Joan Padrosa Pulido
TBTanny Daniela Barreto
Tanny Daniela Barreto
MAManoli Chicote Aldana
Manoli Chicote Aldana
JMJavier Marco-Hernández
Javier Marco-Hernández
Background: Despite the increasing number of ICU admissions among patients with solid tumours, there is a lack of tools with which to identify patients who may benefit from critical support. We aim to characterize the clinical profile and outcomes of patients with solid malignancies admitted to the ICU. Methods: Retrospective observational study of patients with cancer non-electively admitted to the ICU of the Hospital Clinic of Barcelona (Spain) between January 2019 and December 2019. Data regarding patient and neoplasm characteristics, ICU admission features and outcomes were collected from medical records. Results: 97 ICU admissions of 84 patients were analysed. Lung cancer (22.6%) was the most frequent neoplasm. Most of the patients had metastatic disease (79.5%) and were receiving oncological treatment (75%). The main reason for ICU admission was respiratory failure (38%). Intra-ICU and in-hospital mortality rates were 9.4% and 24%, respectively. Mortality rates at 1, 3 and 6 months were 19.6%, 36.1% and 53.6%. Liver metastasis, gastrointestinal cancer, hypoalbuminemia, elevated basal C-reactive protein, ECOG-PS greater than 2 at ICU admission, admission from ward and an APACHE II score over 14 were related to higher mortality. Functional status was severely affected at discharge, and oncological treatment was definitively discontinued in 40% of the patients. Conclusion: Medium-term mortality and functional deterioration of patients with solid cancers non-electively admitted to the ICU are high. Surrogate markers of cachexia, liver metastasis and poor ECOG-PS at ICU admission are risk factors for mortality.

29 August 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
VAVíctor Albarrán-Artahona
Víctor Albarrán-Artahona
JLJuan-Carlos Laguna
Juan-Carlos Laguna
TGTeresa Gorria
Teresa Gorria
JTJavier Torres-Jiménez
Javier Torres-Jiménez
MPMariona Pascal
Mariona Pascal
LMLaura Mezquita
Laura Mezquita
Immunotherapy has dramatically changed the therapeutic landscape of oncology, and has become standard of care in multiple cancer types in front or late lines of therapy, with some longstanding responses and outstanding results. Notwithstanding, its use has brought a totally unique spectrum of adverse events, characterized by a myriad of diverse manifestations affecting nearly every organ and system of the body, including the endocrine, nervous, cardiac, respiratory and gastrointestinal systems. Uncommon adverse events, defined as those occurring in less than 1% of patients, comprise an even more heterogeneous group of diseases that are being seen more recurrently as the use of immune check-point inhibitors increases and indications spread in different tumor types and stages. Here, we comprehensively review some uncommon, but exceedingly important, immune-related adverse events, with special emphasis in the clinical approach and diagnostic workup, aiming to reunite the evidence published previously, allowing an increase in awareness and knowledge from all specialists implicated in the diagnosis, treatment, and care of cancer patients treated with immunotherapy.

26 March 2024 in British Journal of Cancer
Verified
Journal Article
Closed access
PDF file
JLJuan-Carlos Laguna
Juan-Carlos Laguna
BPBelén Pastor
Belén Pastor
INIrene Nalda
Irene Nalda
SHSara Hijazo-Pechero
Sara Hijazo-Pechero
CTCristina Teixido
Cristina Teixido
LMLaura Mezquita
Laura Mezquita

16 July 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
ESElia Seguí
Elia Seguí
JTJuan Torres
Juan Torres
EAEdouard Auclin
Edouard Auclin
DCDavid Casadevall
David Casadevall
SCSara Peiro Carmona
Sara Peiro Carmona
LMLaura Mezquita
Laura Mezquita
Purpose: Inflammation and neutrophils play a central role in both Covid-19 disease and cancer. We aimed to assess the impact of pre-existing tumor-related inflammation on Covid-19 outcomes in patients with cancer and to elucidate the role of circulating neutrophil subpopulations. Methods: We conducted a multicenter retrospective analysis of 524 patients with cancer and SARS-CoV-2 infection, assessing the relationship between clinical outcomes and circulating inflammatory biomarkers collected before and during Covid-19 infection. Additionally, a unicenter prospective cohort provided data for an exploratory analysis, assessing the immunophenotype of circulating neutrophils and inflammatory cytokines. The primary endpoints were 30-day mortality and severity of Covid-19 disease. Results: Prior to Covid-19, 25% of patients with cancer exhibited elevated dNLR, which increase to 55% at the time of Covid-19 diagnosis. We developed the FLARE score, incorporating both tumor and infection-induced inflammation, which categorized patients into four prognostic groups. The poor prognostic group had a 30-day mortality rate of 68%, significantly higher than the 23% in the favorable group (p<0.0001). The score proved to be an independent predictor of early mortality. The prospective analysis revealed a shift towards immature forms of neutrophils and higher IL-6 levels in patients with cancer and severe Covid-19 infection. Conclusions: A pre-existing tumor-induced pro-inflammatory state significantly impacts Covid-19 outcomes in patients with cancer. The FLARE score serves as an easy-to-use and worldwide accessible effective tool to predict outcomes in this population, while circulating neutrophil subpopulations might provide additional information and could help refine outcome prediction.